Current management of unresectable non-small-cell lung cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The past S years have witnessed an evolution in the management of unresectable non-small-cell lung cancer (NSCLC) in the United States. Combined-modality treatment with chemotherapy plus irradiation has become the standard of care for stage III (locally advanced) disease. Most patients with stage IIIB disease and cytology-positive pleural effusion are now considered candidates for chemotherapy, as are those with stage IV disease. Studies have suggested that cisplatin (Platinol), either alone or in combination therapy, is likely to improve survival in advanced NSCLC. Several newer agents have also shown activity. As single agents, vinorelbine (Navelbine) and carboplatin (Paraplatin) have resulted in prolonged survival in randomized trials. Combined treatment with cisplatin plus vinorelbine has shown a significant advantage over standard cisplatin-based regimens. The combination of cisplatin and vinorelbine is currently a reasonable community standard for the treatment of NSCLC. Other agents of interest include paclitaxel (Taxol), docetaxel (Taxotere), gemcitabine (Gemzar), and irinotecan (Camptosar). The use of these treatments in combination with other therapies warrants further investigation.

Original languageEnglish (US)
Pages (from-to)11-15
Number of pages5
JournalOncology (Williston Park, N.Y.)
Volume11
Issue number10 SUPPL. 12
StatePublished - 1997
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
irinotecan
Cisplatin
docetaxel
gemcitabine
Carboplatin
Paclitaxel
Therapeutics
Drug Therapy
Survival
Pleural Effusion
Standard of Care
Cell Biology
vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

Current management of unresectable non-small-cell lung cancer. / Livingston, Robert B.

In: Oncology (Williston Park, N.Y.), Vol. 11, No. 10 SUPPL. 12, 1997, p. 11-15.

Research output: Contribution to journalArticle

@article{36fd2b365d104f13b1798a7ad95f6a55,
title = "Current management of unresectable non-small-cell lung cancer",
abstract = "The past S years have witnessed an evolution in the management of unresectable non-small-cell lung cancer (NSCLC) in the United States. Combined-modality treatment with chemotherapy plus irradiation has become the standard of care for stage III (locally advanced) disease. Most patients with stage IIIB disease and cytology-positive pleural effusion are now considered candidates for chemotherapy, as are those with stage IV disease. Studies have suggested that cisplatin (Platinol), either alone or in combination therapy, is likely to improve survival in advanced NSCLC. Several newer agents have also shown activity. As single agents, vinorelbine (Navelbine) and carboplatin (Paraplatin) have resulted in prolonged survival in randomized trials. Combined treatment with cisplatin plus vinorelbine has shown a significant advantage over standard cisplatin-based regimens. The combination of cisplatin and vinorelbine is currently a reasonable community standard for the treatment of NSCLC. Other agents of interest include paclitaxel (Taxol), docetaxel (Taxotere), gemcitabine (Gemzar), and irinotecan (Camptosar). The use of these treatments in combination with other therapies warrants further investigation.",
author = "Livingston, {Robert B}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "11--15",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 12",

}

TY - JOUR

T1 - Current management of unresectable non-small-cell lung cancer

AU - Livingston, Robert B

PY - 1997

Y1 - 1997

N2 - The past S years have witnessed an evolution in the management of unresectable non-small-cell lung cancer (NSCLC) in the United States. Combined-modality treatment with chemotherapy plus irradiation has become the standard of care for stage III (locally advanced) disease. Most patients with stage IIIB disease and cytology-positive pleural effusion are now considered candidates for chemotherapy, as are those with stage IV disease. Studies have suggested that cisplatin (Platinol), either alone or in combination therapy, is likely to improve survival in advanced NSCLC. Several newer agents have also shown activity. As single agents, vinorelbine (Navelbine) and carboplatin (Paraplatin) have resulted in prolonged survival in randomized trials. Combined treatment with cisplatin plus vinorelbine has shown a significant advantage over standard cisplatin-based regimens. The combination of cisplatin and vinorelbine is currently a reasonable community standard for the treatment of NSCLC. Other agents of interest include paclitaxel (Taxol), docetaxel (Taxotere), gemcitabine (Gemzar), and irinotecan (Camptosar). The use of these treatments in combination with other therapies warrants further investigation.

AB - The past S years have witnessed an evolution in the management of unresectable non-small-cell lung cancer (NSCLC) in the United States. Combined-modality treatment with chemotherapy plus irradiation has become the standard of care for stage III (locally advanced) disease. Most patients with stage IIIB disease and cytology-positive pleural effusion are now considered candidates for chemotherapy, as are those with stage IV disease. Studies have suggested that cisplatin (Platinol), either alone or in combination therapy, is likely to improve survival in advanced NSCLC. Several newer agents have also shown activity. As single agents, vinorelbine (Navelbine) and carboplatin (Paraplatin) have resulted in prolonged survival in randomized trials. Combined treatment with cisplatin plus vinorelbine has shown a significant advantage over standard cisplatin-based regimens. The combination of cisplatin and vinorelbine is currently a reasonable community standard for the treatment of NSCLC. Other agents of interest include paclitaxel (Taxol), docetaxel (Taxotere), gemcitabine (Gemzar), and irinotecan (Camptosar). The use of these treatments in combination with other therapies warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0030785451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030785451&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 11

EP - 15

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 10 SUPPL. 12

ER -